



Innovative Medicines Initiative

# The Members States Perspective

**Stavros Malas**


**Chair – States Representatives Group (SRG)**



**efpia**

---

# IMI-Governance



# States Representatives Group Composition



- EU Member States



- EU Associated/Candidate Countries



# States Representatives Group Mission

---



- Facilitate the dissemination of information within their own countries
  - Provide an opinion on
    - the annual scientific priorities
    - the outcome of the evaluation process
    - the update of the Research Agenda
    - the activities of the IMI-JU
    - the changes to the call and the evaluation process
    - IPR rules rules
    - the composition of the experts for the SC
- 



# States Representatives Group Perceptions

---



- 2004-2008
  - Takes 20% of FP7 budget – is it going to work?
  - Pre-competitive research notion – what does it mean?
  - Will all EU academics benefit from IMI funding?
  - Are IP rules conducive to Academia/SME-Pharma collaborations?
  - Is funding model adequate?



# States Representatives Group Realities – Participation to calls 1



- 20% of FP7 – Tremendous Response to first two calls -more response than under FP6

|                         | CALL 1 | CALL 2 |
|-------------------------|--------|--------|
| Topics                  | 18     | 9      |
| Expressions of Interest | 134    | 124    |
| Participants            | 1.294  | 1.118  |


- Success rate very low 5-10% for research-intensive projects



# States Representatives Group Realities- Participation to calls 2



Research potential varies across the EU



# States Representatives Group

## Realities- Overheads 1

---



- Why is it an issue?
  - FP7
    - 100 € direct costs
    - 60 € direct costs
    - 75% funding-120 €
  - IMI
    - 100 € direct costs
    - 20 € direct costs
    - 75% funding-90 €





# States Representatives Group

## Realities- Overheads 2

---



- Overhead issue
    - SRG position
      - Change o/h to FP7 rules (should not apply to Pharmas)
    - EFPIA position
      - Change to o/h FP7 rules (should not apply to Pharmas)
    - Commission position
      - Not yet decided
    - GB position
      - TBD July 2010
- 



- IPR issues
  - January 2009 GB sets up IPR Working Group
  - February 2009, first recommendations to GB
    - **'Clarifications' issues**
      - Issues which need to be **further explained** or elaborated, but do **not require change** in the **fundamental principles** underlying the written policy.
    - **'Policy issues'**
      - Issues that do **impact** the substance and **fundamental principles** underlying the written policy and where **additional explanations would not suffice** to address the concerns. **Possible action followed: amendments of the articles**
  - Further discussion on **Policy issues** – Ongoing



- Concluding remarks
  - Strong enthusiasm so far for stage 1 submissions, is it going to continue (low success rate)?
  - SRG expects to have o/h and IPR issues resolved before the third call.
  - Will IMI have a structuring effect on European Research Area?
  - Will notions for P-P collaborations change?
  - FP8?

